BMRN — BioMarin Pharmaceutical Share News
0.000.00%
Last trade - 00:00- $10.85bn
- $14.16bn
- $3.22bn
BioMarin rises after genetic disorder drug meets main goal in trial
BioMarin's drug shows significant growth gains in children in late-stage trial (updated)
BioMarin's drug shows significant growth gains in children in late-stage trial
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
BioMarin falls after genetic disease therapy shows mixed results in study
Brief: Biomarin Provides Update On Phase 3 Trial For Bmn 401 In Children Aged 1-12 With Enpp1 Deficiency
BioMarin's genetic disease therapy shows mixed results in late-stage study (updated)
BioMarin's genetic disease therapy shows mixed results in late-stage study
BioMarin Q1 revenue rises, beats estimates
Brief: Biomarin Presents New Data On The Effect Of Long-Term Treatment With Voxzogo® (Vosoritide) On Arm Span, Bone Health And Growth In Children With Achondroplasia
Brief: Biomarin Announces Board Leadership Transition
BioMarin stops mid-stage trials of bone disorder treatment
Brief: Biomarin Pharmaceutical Inc - Discontinues Phase 2 Voxzogo Trials In Turner Syndrome, Shox-Deficiency, Acan-Deficiency - SEC Filing
Brief: U.S. Food And Drug Administration Approves Biomarin's Palynziq® (Pegvaliase-Pqpz) For Adolescents 12 Years Of Age And Older With Phenylketonuria (Pku)
Ascendis wins U.S. approval for therapy for children with dwarfism (updated)
Ascendis wins U.S. approval for therapy for children with dwarfism
BioMarin Pharmaceutical's Q4 revenue up 17%, beats expectations
BridgeBio's oral drug boosts growth in children with dwarfism in late-stage trial (updated)
BridgeBio's oral drug improves growth in children with dwarfism in late-stage study